[go: up one dir, main page]

MX2017008486A - Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. - Google Patents

Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.

Info

Publication number
MX2017008486A
MX2017008486A MX2017008486A MX2017008486A MX2017008486A MX 2017008486 A MX2017008486 A MX 2017008486A MX 2017008486 A MX2017008486 A MX 2017008486A MX 2017008486 A MX2017008486 A MX 2017008486A MX 2017008486 A MX2017008486 A MX 2017008486A
Authority
MX
Mexico
Prior art keywords
btk inhibitor
dosing regimen
phase
combination
inhibitor combinations
Prior art date
Application number
MX2017008486A
Other languages
English (en)
Inventor
M Jaglowski Samantha
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017008486A publication Critical patent/MX2017008486A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos y combinación de regímenes de dosificación para administrar una combinación de un inhibidor de BTK (por ejemplo, ibrutinib) y un agente terapéutico anti-CD20 para el tratamiento de una malignidad hematológica. En un aspecto es una combinación de regímenes de dosificación para el tratamiento de una malignidad hematológica en un sujeto en la necesidad del mismo que comprende una primera fase y una segunda fase, en donde la primera fase es una administración de un inhibidor BTK como un tratamiento de un agente simple para una primera extensión de periodo de tiempo, y una segunda fase como una administración de una combinación del inhibidor BTK y un agente terapéutico anti-CD20 para una segunda extensión de periodo de tiempo. En una modalidad, la primera extensión del periodo de tiempo es un periodo de hasta 90 días.
MX2017008486A 2014-12-23 2015-12-22 Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. MX2017008486A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096284P 2014-12-23 2014-12-23
PCT/US2015/067504 WO2016106381A1 (en) 2014-12-23 2015-12-22 Btk inhibitor combinations and dosing regimen

Publications (1)

Publication Number Publication Date
MX2017008486A true MX2017008486A (es) 2017-09-19

Family

ID=56151542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008486A MX2017008486A (es) 2014-12-23 2015-12-22 Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.

Country Status (10)

Country Link
US (1) US20170360796A1 (es)
EP (1) EP3236968A4 (es)
JP (1) JP2018503610A (es)
CN (1) CN107106565A (es)
AU (1) AU2015369665A1 (es)
BR (1) BR112017013580A2 (es)
CA (1) CA2970043A1 (es)
HK (1) HK1245153A1 (es)
MX (1) MX2017008486A (es)
WO (1) WO2016106381A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702485A (en) 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
US20190224204A1 (en) * 2016-08-19 2019-07-25 Cipla Limited Pharmaceutical compositions of ibrutinib
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
WO2019127008A1 (zh) * 2017-12-26 2019-07-04 清华大学 一种靶向降解btk的化合物及其应用
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
AR122307A1 (es) * 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN120826242A (zh) * 2023-03-09 2025-10-21 浙江特瑞思药业股份有限公司 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
KR101871436B1 (ko) * 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
NZ702485A (en) * 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
MX391121B (es) * 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
GB201207305D0 (en) * 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
AU2014244518A1 (en) * 2013-03-14 2015-09-17 Pharmacyclics Llc Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
MX366449B (es) * 2013-06-07 2019-07-09 Rhizen Pharmaceuticals Sa Inhibidores de pi3 cinasa delta y gama selectivos duales.
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

Also Published As

Publication number Publication date
HK1245153A1 (zh) 2018-08-24
EP3236968A1 (en) 2017-11-01
AU2015369665A1 (en) 2017-06-29
CN107106565A (zh) 2017-08-29
EP3236968A4 (en) 2018-08-01
JP2018503610A (ja) 2018-02-08
WO2016106381A1 (en) 2016-06-30
US20170360796A1 (en) 2017-12-21
BR112017013580A2 (pt) 2018-04-10
CA2970043A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
MX378273B (es) Compuestos activos hacia bromodominios.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502355B1 (en) Pharmaceutical composition
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
MY174670A (en) Anti-folr1 immunoconjugate dosing regimens
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2017000366A (es) Terapia de combinacion para el cancer.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018002554A (es) Combinaciones de inhibidores de btk para tratar mieloma multiple.
MA39743A (fr) Fumarate de diméthyle et régimes de vaccination
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом
IN2014DE00822A (es)
MY203104A (en) Anti-folr1 immunoconjugate dosing regimens
UA107884C2 (en) Combined anti-tuberculosis drug
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
IN2014DE00818A (es)